ICICI Prudential Asset Management Co Ltd Buys 46 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

ICICI Prudential Asset Management Co Ltd raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating) by 17.7% in the first quarter, Holdings Channel reports. The fund owned 306 shares of the biopharmaceutical company’s stock after acquiring an additional 46 shares during the period. ICICI Prudential Asset Management Co Ltd’s holdings in Regeneron Pharmaceuticals were worth $212,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Glassman Wealth Services raised its holdings in shares of Regeneron Pharmaceuticals by 19.5% in the first quarter. Glassman Wealth Services now owns 92 shares of the biopharmaceutical company’s stock valued at $64,000 after buying an additional 15 shares during the last quarter. Minot Wealth Management LLC raised its holdings in shares of Regeneron Pharmaceuticals by 3.8% in the first quarter. Minot Wealth Management LLC now owns 408 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 15 shares during the last quarter. Stratos Wealth Partners LTD. raised its holdings in shares of Regeneron Pharmaceuticals by 3.1% in the first quarter. Stratos Wealth Partners LTD. now owns 535 shares of the biopharmaceutical company’s stock valued at $374,000 after buying an additional 16 shares during the last quarter. Capital Analysts LLC raised its holdings in shares of Regeneron Pharmaceuticals by 3.8% in the fourth quarter. Capital Analysts LLC now owns 463 shares of the biopharmaceutical company’s stock valued at $292,000 after buying an additional 17 shares during the last quarter. Finally, Koss Olinger Consulting LLC raised its holdings in shares of Regeneron Pharmaceuticals by 3.9% in the fourth quarter. Koss Olinger Consulting LLC now owns 485 shares of the biopharmaceutical company’s stock valued at $306,000 after buying an additional 18 shares during the last quarter. 83.83% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on REGN. Cowen lifted their price objective on Regeneron Pharmaceuticals from $635.00 to $645.00 and gave the stock a “market perform” rating in a research report on Wednesday, July 20th. Cowen lifted their price objective on Regeneron Pharmaceuticals from $635.00 to $645.00 in a research report on Wednesday, July 20th. Morgan Stanley lifted their price objective on Regeneron Pharmaceuticals from $619.00 to $625.00 and gave the stock an “equal weight” rating in a research report on Thursday. Barclays lifted their price objective on Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 12th. Finally, Evercore ISI set a $635.00 price objective on Regeneron Pharmaceuticals in a research report on Monday, June 20th. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $697.85.

Regeneron Pharmaceuticals Trading Down 0.2 %

NASDAQ:REGN opened at $613.61 on Friday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $538.01 and a fifty-two week high of $747.42. The company has a debt-to-equity ratio of 0.13, a current ratio of 5.12 and a quick ratio of 4.09. The stock has a market capitalization of $66.60 billion, a PE ratio of 12.25, a price-to-earnings-growth ratio of 1.88 and a beta of 0.29. The business’s 50-day simple moving average is $598.47 and its 200-day simple moving average is $635.98.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last released its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported $9.77 earnings per share for the quarter, missing the consensus estimate of $9.94 by ($0.17). Regeneron Pharmaceuticals had a net margin of 39.97% and a return on equity of 36.17%. The business had revenue of $2.86 billion for the quarter, compared to the consensus estimate of $2.80 billion. During the same quarter last year, the firm earned $27.97 EPS. The company’s revenue for the quarter was down 44.4% on a year-over-year basis. Sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 40.89 earnings per share for the current fiscal year.

Insider Activity

In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,100 shares of the business’s stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $581.53, for a total value of $639,683.00. Following the sale, the executive vice president now owns 19,644 shares in the company, valued at approximately $11,423,575.32. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 8.99% of the stock is currently owned by company insiders.

Regeneron Pharmaceuticals Profile

(Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Stories

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGNGet Rating).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.